Seeking Alpha

A little more than a year ago, I wrote my first article on Trovagene (TROV). I penned it in response to an SA article I read that touted its "billion-dollar" potential. This was an outlandish claim considering TROV's $51M market cap, a thimble's worth of revenue and four employees. Could the market be this inefficient? After perusing the company's amateurish website and reading about the Xenomics flame out, I concluded that the bullish author was either a paid promoter, a long trying desperately to create support for his losing position or a connoisseur of psilocybin mushrooms. There was no evidence that the company would be able to monetize its patents on nucleic acid testing in...

Only subscribers can access this article, which is part of the PRO research library covering 3,768 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: